Thomas H. Large, Ph.D.
World-leading expert in a systems approach to CNS drug discovery + development
Large- and mid-pharma experience in unmet patient needs, new product planning and commercial analytics
Successful partnering with large pharma, biotech, CRO, academic and government organizations
Corporate, Board and Investor presentations and M+A due diligence
Kerry L. Spear, Ph.D.
Kerry Spear, co-founder and Chief Science Officer of Blue Oak Pharmaceuticals, is responsible for initiating and advancing company programs from the discovery phase to IND filings. He is a pioneer in the (re)emerging area of phenotypic drug discovery and the application of high-content phenotypic data to focus and accelerate lead generation and lead optimization processes. Kerry conceived and developed Blue Oak’s ADEPtTM technology, an innovative method for identifying novel privileged structures that are especially relevant to CNS diseases using a phenotypic screening approach to drug discovery. Trained in natural products synthesis, he brings to Blue Oak over 36 years of experience in both Pharma and Biotech. He has led programs that cover a broad range of drug discovery research and which have resulted in 15 NCEs advancing into clinical development in multiple therapeutic areas (e.g., CNS, oncology, hematology, urology, respiratory, cardiovascular). Kerry has also actively managed multidisciplinary outsourcing efforts at the international level to accelerate timelines and reduce costs while maintaining quality. Dr. Spear is an Adjunct Professor of Medicinal Chemistry at Fudan University (Shanghai, China). He is co-inventor of over 46 published patents and patent applications and is co-author of 33 peer-reviewed publications. Kerry completed a postdoctoral fellowship at the University of California, Berkeley under the direction of Professor Paul A. Bartlett. He earned a Ph.D. degree in organic chemistry from the University of Wisconsin, Madison and a B.S. degree from Juniata College.